JPWO2021231851A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021231851A5 JPWO2021231851A5 JP2022569031A JP2022569031A JPWO2021231851A5 JP WO2021231851 A5 JPWO2021231851 A5 JP WO2021231851A5 JP 2022569031 A JP2022569031 A JP 2022569031A JP 2022569031 A JP2022569031 A JP 2022569031A JP WO2021231851 A5 JPWO2021231851 A5 JP WO2021231851A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- level
- actriib ligand
- ligand trap
- mtor inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 48
- 229940079593 drug Drugs 0.000 claims 47
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 36
- 239000003446 ligand Substances 0.000 claims 36
- 229940124302 mTOR inhibitor Drugs 0.000 claims 28
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 28
- 102000001554 Hemoglobins Human genes 0.000 claims 14
- 108010054147 Hemoglobins Proteins 0.000 claims 14
- 208000007502 anemia Diseases 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 230000010437 erythropoiesis Effects 0.000 claims 10
- 210000001995 reticulocyte Anatomy 0.000 claims 9
- 230000002708 enhancing effect Effects 0.000 claims 8
- 210000003743 erythrocyte Anatomy 0.000 claims 8
- 238000005534 hematocrit Methods 0.000 claims 6
- 210000000265 leukocyte Anatomy 0.000 claims 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 4
- 229960002930 sirolimus Drugs 0.000 claims 4
- 208000002903 Thalassemia Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000006288 alpha thalassemia Diseases 0.000 claims 2
- 208000005980 beta thalassemia Diseases 0.000 claims 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063025955P | 2020-05-15 | 2020-05-15 | |
| US63/025,955 | 2020-05-15 | ||
| PCT/US2021/032434 WO2021231851A1 (en) | 2020-05-15 | 2021-05-14 | Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023526590A JP2023526590A (ja) | 2023-06-22 |
| JPWO2021231851A5 true JPWO2021231851A5 (https=) | 2024-05-22 |
| JP2023526590A5 JP2023526590A5 (https=) | 2024-05-22 |
Family
ID=78525025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022569031A Pending JP2023526590A (ja) | 2020-05-15 | 2021-05-14 | ＡｃｔＲＩＩＢリガンドトラップ及びｍＴＯＲ阻害剤を使用して貧血を治療するための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230210827A1 (https=) |
| EP (2) | EP4149441A4 (https=) |
| JP (1) | JP2023526590A (https=) |
| KR (1) | KR20230010641A (https=) |
| CN (1) | CN115551487A (https=) |
| AU (1) | AU2021273065A1 (https=) |
| BR (1) | BR112022022830A2 (https=) |
| CA (1) | CA3177632A1 (https=) |
| IL (1) | IL298156A (https=) |
| MX (1) | MX2022014080A (https=) |
| WO (1) | WO2021231851A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5561138A (en) * | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
| EP1771470B1 (en) | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| SMT202300222T1 (it) | 2008-08-14 | 2023-09-06 | Acceleron Pharma Inc | Trappole di gdf |
| CN104968801B (zh) | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| IL258574B2 (en) * | 2015-11-11 | 2025-01-01 | Novartis Ag | Uses of myostatin antagonists, combinations containing them and their uses |
| PL3490582T3 (pl) * | 2016-07-27 | 2024-09-23 | Acceleron Pharma Inc. | Kompozycje do zastosowania w leczeniu mielofibrozy |
| WO2018185341A1 (en) * | 2017-04-07 | 2018-10-11 | Ospedale San Raffaele S.R.L. | Regulator of bmp-smad signaling and uses thereof |
| HRP20241477T1 (hr) * | 2017-06-14 | 2025-01-03 | Celgene Corporation | Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom |
| US20220372136A1 (en) * | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating anemia of chronic disease |
-
2021
- 2021-05-14 CA CA3177632A patent/CA3177632A1/en active Pending
- 2021-05-14 CN CN202180034458.7A patent/CN115551487A/zh active Pending
- 2021-05-14 BR BR112022022830A patent/BR112022022830A2/pt unknown
- 2021-05-14 AU AU2021273065A patent/AU2021273065A1/en active Pending
- 2021-05-14 EP EP21803281.1A patent/EP4149441A4/en not_active Withdrawn
- 2021-05-14 IL IL298156A patent/IL298156A/en unknown
- 2021-05-14 KR KR1020227039375A patent/KR20230010641A/ko active Pending
- 2021-05-14 JP JP2022569031A patent/JP2023526590A/ja active Pending
- 2021-05-14 MX MX2022014080A patent/MX2022014080A/es unknown
- 2021-05-14 WO PCT/US2021/032434 patent/WO2021231851A1/en not_active Ceased
- 2021-05-14 US US17/924,821 patent/US20230210827A1/en active Pending
- 2021-05-14 EP EP25203135.6A patent/EP4649961A3/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Macdougall et al. | A randomized controlled study of iron supplementation in patients treated with erythropoietin | |
| Muñoz et al. | Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion | |
| Tsubakihara et al. | 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease | |
| Paesano et al. | Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women | |
| Jelkmann et al. | Biology of erythropoietin | |
| TWI440457B (zh) | 含檸檬酸及/或檸檬酸鹽之組成物的用途 | |
| CN104884055A (zh) | 柠檬酸铁在治疗慢性肾脏疾病患者中的应用 | |
| JP2021169525A (ja) | 可溶性ピロリン酸第二鉄を用いて鉄欠乏症を治療する方法 | |
| Hayes et al. | Successful reduction of plasma free-hemoglobin using therapeutic plasma exchange: a case report | |
| Ashraf et al. | Metformin-associated lactic acidosis: A case report and review | |
| Vernon et al. | Poisoning and drug overdose | |
| CN115397431A (zh) | 用于治疗涉及全身过度炎症反应的病症的eclitasertib | |
| Sheikhi et al. | Cardiac surgery anesthesia and systemic inflammatory response | |
| Swenson | Severe hyperkalemia as a complication of timolol, a topically applied ß-ADRENERGIC ANTAGONIST | |
| Socha-Banasiak et al. | Metallothioneins in inflammatory bowel diseases: Importance in pathogenesis and potential therapy target | |
| JPWO2021231851A5 (https=) | ||
| Higgins et al. | Anemia in hemodialysis patients: changing concepts in management | |
| JP6578293B2 (ja) | 反応性が低下した患者のエリトロポエチン刺激剤の用量を減少させる方法 | |
| CN114286682A (zh) | 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁 | |
| Li et al. | The roller coaster of lamotrigine levels: Successful treatment of massive lamotrigine overdose with continuous veno-venous hemodiafiltration and rifampin | |
| Huang et al. | Case report: atenolol overdose successfully treated with hemodialysis | |
| Salah et al. | Use of hydroxycobolamin in the prevention of vasoplegic syndrome in adult patients undergoing cardiopulmonary bypass: a controlled prospective trial | |
| JPH11209303A (ja) | 腎不全治療薬及び腎不全患者用食品 | |
| CN101568334A (zh) | 铁代谢改善剂 | |
| Movilli et al. | The role of hematocrit in efficiency of dialysis |